CD19/CD22 双特异性嵌合抗原受体 NK-92 细胞的开发与评价
CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated.
31.6分
★☆☆☆☆
站内排序·非疗效
FRONTIER PAPERS
CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated.
共 1 条
MEMBER ACCOUNT
登录成功会直接打开下一页。